Northwest Biotherapeutics Strengthens Board Capability
Northwest Biotherapeutics (NW Bio), a biotechnology company developing personalised immunotherapy products based in Bethesda, Maryland, has appointed Susan Bayh and Cofer Black as independent directors.
Editas Medicine Appoints John D. Mendlein to Board of Directors
Editas Medicine, a genome editing company based in Cambridge, Mass, has appointed John D. Mendlein to its board of directors. Mendlein has served as CEO of aTyr Pharma since 2011, as well as executive chairman for the company from July 2010 to January 2016.
Amplyx Pharmaceuticals Announces Trio of Appointments
Amplyx Pharmaceuticals, a San Diego-based company developing antifungal agents for the treatment of life-threatening fungal infections, has appointed Michael Hodges as chief medical officer, Karen Shaw as vice president of biology, and Elizabeth Gordon as vice president of regulatory affairs. The firm recently raised an USD8.7 million investment from 3×5 Partners, increasing its series B financing to USD49.2 million.
eFFECTOR Therapeutics Secures New Series B Funding
eFFECTOR Therapeutics, an early-stage company focused on the discovery and development of small molecule cancer therapeutics in San Diego, has secured its Series B financing up to USD 56 million. The new funding came from Sectoral Asset Management, a new investor in the syndicate, as well as existing investors. Meanwhile, eFFECTOR Therapeutics appointed Maha Katabi, a partner from Sectoral, to its board of directors.
HemaFlo Therapeutics Names Michael Martino as CEO
HemaFlo Therapeutics, a private biotech company based in Carlsbad, Calif, has appointed Michael A. Martino as President, CEO and Board Director. Martino joined as President and CEO of Ambit Biosciences after its acquisition by Daiichi Sankyo in 2014.
AVROBIO Bolsters Senior Management Team
AVROBIO, a clinical-stage biotechnology company developing transformative cell and gene therapies targeting cancer and rare diseases, has made three senior appointments. Joining the firm’s leadership team are Kim Warren, Head of Operations, Chris Mason, Chief Science Officer, and Deanna Petersen, Chief Business Officer.
Tocagen Names Vice President
Tocagen, a clinical-stage, cancer-selective gene therapy company, has named John Wood vice president of regulatory affairs and quality assurance.
Ascendis Pharma Appoints Chief Medical Officer
Ascendis Pharma, a clinical stage biotechnology company based in Copenhagen, and offices in Palo Alto, has appointed Jonathan A. Leff as Chief Medical Officer to replace Acting Chief Medical Officer Michael Beckert. Beckert will continue his consulting role with the company with a focus on leading the company’s European clinical operations.
